Hangzhou Highlightll Pharmaceutical Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING1
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TLL-018 tablets NCT06396026 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 440 | 2025-10-23 (-5 mo) |
| TLL-018 NCT06887127 |
P3 | Active, not recruiting | Rheumatoid Arthritis | 350 | 2026-12-31 |
| HL-300 NCT07629778 |
P1/2 | Recruiting | Atopic Dermatitis | 156 | 2027-06-30 |
| TLL-018 NCT07748728 |
P2 | Enrolling by invitation | Rheumatoid Arthritis (RA) | 90 | 2027-07-31 |
| TLL-018 NCT07665996 |
P1/2 | Not yet recruiting | Chronic Spontaneous Urticaria (CSU) | 36 | 2027-12-31 |
| TLL-018 tablets NCT07764003 |
P2 | Not yet recruiting | Chronic Spontaneous Urticaria (CSU) | 140 | 2027-12-31 |
| TLL-018 tablets NCT07784816 |
P2/3 | Not yet recruiting | Atopic Dermatitis (AD) | 390 | 2029-09-30 |